Pneumologie 2010

 

 Buy Article Permissions and Reprints

Was ist neu?

• Chronisch obstruktive Lungenerkrankung: Zulassung neuer Medikamente, wie Indacaterol (24h-wirksames inhalatives Beta-2-Mimetikum) und Roflumilast (Phosphodiesterase-4-Inhibitor). Dreier-Kombinationspräparate mit Anticholinergikum, Kortikosteroid und Beta-2-Dilatatoren kommen in Kürze auf den Markt.

• Asthma bronchiale: An neuen Kombinationspräparaten mit inhalativen 24h-Beta-2-Mimetika plus Kortikosteroide wird derzeit gearbeitet.

• Ambulant erworbene Pneumonie: Veröffentlichung der neuen S3-Leitlinie CAP.

• Pulmonale arterielle Hypertonie: Veröffentlichung der neuen S3-Leitlinie PAH.

• Lungenkarzinom: Veröffentlichung der S3-Leitlinie mit neuer Einteilung der TNM-Stadien.

Literatur

• 1 Aliverti S, Blasi F, Zanaboni A M. et al . Duration of antibiotic therapy in hospitalized patients with community-acquired pneumonia.  Eur Respir J. 2009, im Druck; 
  Google Scholar
• 2 Ambrosino N, Vagheggini G. Noninvasive positive pressure ventilation in the acute care setting: where are we?.  Eur Respir J. 2008;  31 874-886
  Google Scholar
• 3 Anevlavis S, Bouros D. Community acquired bacterial pneumonia.  Expert Opin Pharmacother. 2010;  11 361-374
  Google Scholar
• 4 Aspa J, Rajas O, de Castro F R. Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia.  Expert Opin Pharmacother. 2008;  9 229-241
  Google Scholar
• 5 Barst R J, Gibbs J S, Ghofrani H A. et al . Updated evidence-based treatment algorithm in pulmonary arterial hypertension.  J Am Coll Cardiol. 2009;  54 S78-S85
  Google Scholar
• 6 Beeh K M, Beier J. Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways disease.  Adv Ther. 2009;  26 691-699
  Google Scholar
• 7 Beeh K M, Derom E, Kanniess F, Cameron R B, Higgins M W, van As A. Indacaterol, a novel inhaled ß2-agonist, provides sustained 24-h bronchodilation in asthma.  Eur Respir J. 2007;  29 871-878
  Google Scholar
• 8 Boman G, Ludviksdottir D, Janson C. et al . Exhaled nitric oxide and its relationship to airway responsiveness and atopy in asthma.  Respir Med. 2008;  93 552-556
  Google Scholar
• 9 Calverley P M A, Rabe K F, Goehring U -M, Kristiansen S, Fabbri L M, Martinez F J. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.  Lancet. 2009;  374 685-694
  Google Scholar
• 10 Cazzola M, Matera M G. Emerging inhaled bronchodilators: an update.  Eur Respir J. 2009;  34 757-769
  Google Scholar
• 11 Chanez P, Burge P S, Dahl R. et al . Aclidinium bromide provides long-acting bronchodilation in patients with COPD.  Pulm Phamacol Therapeutics. 2010;  23 15-21
  Google Scholar
• 12 de Jongste J C, Carraro S, Hop W C, Baraldi E. Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma.  Am J Respir Crit Care Med. 2009;  179 93-97
  Google Scholar
• 13 de Vries F, Setakis E, Zhang B, van Staa T P. Long-acting beta2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study with the General Practice Research Database.  Eur Respir J. 2010, im Druck; 
  Google Scholar
• 14 Dryden M, Hand K, Davey P. Antibiotics for community-acquired pneumonia.  J Antimicrob Chemother. 2009;  64 1123-1125
  Google Scholar
• 15 Dweik R A, Sorkness R L, Wenzel S. et al . Use of exhaled nitric oxide measurement to identify a reactiv, at-risk phenotype among patients with asthma.  Am J Respir Crit Care Med. 2010, im Druck; 
  Google Scholar
• 16 Fabbri L M, Calverley P MA, Izquierdo-Alonso J L. et al . Roflumilast in moderate to severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised trials.  Lancet. 2009;  374 695-703
  Google Scholar
• 17 Fabbri L M, Luppi F, Beghe B, Rabe K F. Complex chronic comorbidities of COPD.  Eur Respir J. 2008;  31 212
  Google Scholar
• 18 Galié N, Hoeper M M, Humpert M. et al . Guidelines on diagnosis and treatment of pulmonary aterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).  Eur Heart J. 2009;  30 2493-2537
  Google Scholar
• 19 Gavalda A, Miralpeix M, Ramos I. et al . Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorabale pharmacological profile.  J Pharmacol Exp Ther. 2009, im Druck; 
  Google Scholar
• 20 Goeckenjan G, Sitter H, Thomas M. et al . Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Interdiziplinäre S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin und der Deutschen Krebsgesellschaft.  Pneumologie. 2010;  2 e1-e164
  Google Scholar
• 21 Hirsh V. Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach.  Curr Oncol. 2010;  17 12-23
  Google Scholar
• 22 Höffken G, Lorenz J, Kern W. et al . Epidemiologie, Diagnostik, antimikrobielle Therapie und Management von erwachsenen Patienten mit ambulant erworbenen unteren Atemwegsinfektion sowie ambulant erworbener Pneumonie – Update 2009.  Pneumologie. 2009;  63 e1-e68
  Google Scholar
• 23 Höffken G, Lorenz J, Kern W. et al . Epidemiologie, Diagnostik, antimikrobielle Therapie und Management von erwachsenen Patienten mit ambulant erworbenen unteren Atemwegsinfektionen sowie ambulant erworbener Pneumonie – Update 2009. S3-Leitlinie der Paul-Ehrlich-Gesellschaft für Chemotherapie, der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin, der Deutschen Gesellschaft für Infektiologie und vom Kompetenznetzwerk (CAPNETZ).  Pneumologie. 2009;  63 e1-e68
  Google Scholar
• 24 Jaeschke R, O’Byrne P M, Mejza F. et al . The safety of long-acting ß-Agonists among patients wiht asthma using inhaled corticosteroids. Systematic review and metaanalysis.  Am J Respir Crit Care Med. 2008;  178 1009-1016
  Google Scholar
• 25 Joos G F, Schelfhout V J, Pauwels R A. et al . Bronchodilatory effects of aclidinium bromide, along-acting muscarinic antagonist in COPD patients.  Respir Med. 2009, im Druck; 
  Google Scholar
• 26 Lim W S, Baudouin S V, George R C. et al . BTS guidelines for the management of community acquired pneumonia in adults: update 2009.  Thorax. 2009;  64 iii1-iii55
  Google Scholar
• 27 Pearlman D S, Greos L, Laforce C, Orevillo C, Owen R, Higgins M W. Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma.  Ann Allergy Asthma Immunol. 2008;  101 90-95
  Google Scholar
• 28 Petsky H L, Cates C J, Li A M, Kynaston J A, Turner C, Chang A B. Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults.  Cochrane Database Syst Rev. 2008;  2 CD006340
  Google Scholar
• 29 Rennard S I, Bantje T, Centanni S. et al . A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.  Respir Med. 2008;  102 1033-1044
  Google Scholar
• 30 Rossi A, Maione P, Sacco P C, Ambrosio R, Falanga M, Gridelli C. Vascular endothelial growth factor receptoras target for advanced non-smallcell lung cancer therapy.  Curr Drug Targets. 2010, im Druck; 
  Google Scholar
• 31 Sears M R, Ottosson A, Radner F, Suissa S. Long-acting ß-agonists: a review of formoterol safety data from asthma clinical trials.  Eur Respir J. 2009;  33 21-32
  Google Scholar
• 32 Sterman D H, Mehta A C, Wood D E. et al . A multicenter pilot study of a bronchial valve for the treatment of severe emphysema.  Respiration. 2010;  79 222-233
  Google Scholar
• 33 Vosswinckel R, Reichenberger F, Gall H, Seeger W, Grimminger F, Ghofrani H A. Therapie der pulmonalarteriellen Hypertonie.  Internist. 2009;  50 1104-1109
  Google Scholar

Dr. med. Anja Häussermann

Robert-Koch-Klinik

Nikolai-Rumjanzew-Str. 100

04207 Leipzig

Email: anja.haeussermann@gmx.de